中文摘要：

目的：观察基质细胞衍生因子1‐α（stromal cell derived factor 1‐α，SDF1‐α）受体抑制剂AMD3100联用索拉非尼对肝细胞肝癌（HCC）裸鼠的疗效。方法：建立肝细胞肝癌原位裸鼠模型，分为对照组、索拉非尼组、索拉非尼＋ AMD3100组，每组6只。索拉非尼组给予索拉非尼30 mg／（kg ＆183; d）灌胃；索拉非尼＋ AMD3100组在给予索拉非尼灌胃的基础上，给予AMD31002．5 mg／（kg ＆183; d）腹腔注射；对照组给予0．9％氯化钠液灌胃。比较三组的肿瘤肝内播散情况、肿瘤大小、肺转移情况和裸鼠的生存时间。结果：在索拉非尼治疗的基础上，联用AMD3100能够明显抑制索拉非尼引起的 HCC肝内侵袭和转移，进一步减小肿瘤体积，减少肺转移，延长荷瘤裸鼠的生存期。结论：SDF1‐α受体抑制剂AMD3100能够增强索拉非尼对HCC的疗效。

英文摘要：

Objective：To investigate the effect of AMD3100 ,an inhibitor of receptor of stromal cell derived factor 1‐α （SDF1‐α） ,combined with sorafenib on nude mice with hepatocellular carcinoma （HCC） .Methods：Nude mice models of HCC in situ was established and the mice were divided into control group ,sorafenib group and sorafenib combined with AMD3100 group , with six mice in each group .In sorafenib group ,sorafenib 30 mg/（kg ＆183; d） was given by garage .In sorafenib combined with AMD3100 group ,AMD3100 2 .5 mg/（kg ＆183; d） was administrated by intraperitoneal injection based on the method of sorafenib group .In the control group ,0 .9% sodium chloride solution was given by garage . The intrahepatic invasion , the tumor volume ,the situation of pulmonary metastasis and the survival time of nude mice ,were compared among the three groups . Results：When sorafenib was combined with AMD3100 ,the intrahepatic invasion and metastasis of HCC caused by sorafenib could be significantly inhibited .Thus the tumor volume was decreased and the pulmonary metastasis could be reduced .The survival time was prolonged .Conclusions：AMD3100 ,a SDF1‐α receptor inhibitor ,can enhance the efficacy of sorafenib .